Recommendations for Topical Corticosteroid Use and the Role of Alternative, Advanced Targeted Topical Treatments in the Treatment of Chronic Inflammatory Skin Diseases.
Safety concerns associated with topical corticosteroids (TCS) have been increasingly recognized and well documented in medical literature for many decades. In response, advanced targeted topical (ATT) therapies have emerged as safer, effective alternatives for managing chronic inflammatory skin diseases. In this review, a group of experienced dermatology nurse practitioners (NPs) and physician assistants/associates (PAs) summarize key consensus statements from a 2025 physician-expert-panel literature review and consensus statement publication addressing the safety and efficacy of TCS and the role of ATT therapies for chronic inflammatory skin diseases. It highlights practical recommendations for incorporating ATT therapies into clinical practice and emphasizes the vital role of NPs and PAs in monitoring cumulative corticosteroid exposure to minimize the risk of both cutaneous and systemic adverse effects associated with TCS use.
Authors
- Robert Higham
- Julie Agopian (ORCID: https://orcid.org/0000-0003-4094-6258)
- Matthew Brunner
- Amber Blair
- Diane T. Hanna (ORCID: https://orcid.org/0000-0003-1162-9341)
- Melissa Seal
- Douglas DiRuggiero (ORCID: https://orcid.org/0000-0003-1362-4309)
- Andrew Baker (ORCID: https://orcid.org/0000-0002-6312-5172)
- Melodie Young
- Justin Love
- Avery Dinallo
- Kristin Rygg
- Aaron Sookhoo
Institutions
- Meridian Institute (US)
- Loma Linda University (US)
- Skin Cancer Foundation (US)
- Sherman Oaks Hospital (US)
- Society of Economic Geologists (US)
- Dermatology, Laser & Vein Specialists of the Carolinas (US)
- Suncoast Hospice Institute (US)
- Institute of Dermatology (TH)
- Dallas Nephrology Associates (US)
- Atara Biotherapeutics (United States) (US)
- Orthopedic One (US)
Publication Details
- Journal
- PubMed
- Published
- 2025-01-01
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Sanofi
- Incyte
- Galderma